Inhibition of Integrin-Mediated Platelet Aggregation, Fibrinogen-Binding, and Interactions with Extracellular Matrix by Nonpeptidic Mimetics of Arg-Gly-Asp

Summary

The interaction of the activated platelet integrin, glycoprotein IIb-IIIa (GPIIb-IIIa) with fibrinogen and von-Wille-brand factor (vWF) is essential for platelet aggregation. The minimal structure required for this integrin’s binding to fibrinogen is the Arg-Gly-Asp (RGD) sequence. Inasmuch as normal level of GPIIb-IIIa-RGD interactions are required for maintaining hemostasis, elevated platelet aggregation can cause adverse pathological effects. We have previously reported that nonpeptidic mimetics of RGD, consisting of carboxylate and guanidinium groups of Asp and Arg divided by a linear 11-atom spacer, acquired a significant affinity for the GPIIb-IIIa integrin and inhibited platelet aggregation. The structural requirements for the interactions of the RGD sequence with GPIIb-IIIa and the inhibitory potential of a newly designed series of mimetics on platelet aggregation and interactions with extracellular matrix (ECM) were assayed herein. Adenosine-diphosphate (ADP)-induced platelet aggregation was inhibited in a dose-dependent manner by various RGD mimetics, with a maximal inhibition of 80-100% with an IC₅₀ of 3 μM for the most potent inhibitor, NS-11 which a six-membered ring was introduced into the spacer chain, which exceeded the IC₅₀ attained with the original RGDS peptide. The inhibitory effect of the RGD mimetics was attributed to their specific interaction with the GPIIb-IIIa integrin, since these mimetics inhibited the binding of the PAC-1 mAb to GPIIb-IIIA. Furthermore, the binding of ¹²⁵I-labeled fibrinogen to platelets was inhibited by the RGD surrogates in a dose-dependent and saturable manner. The RGD-mimetics also inhibited up to 70% the adhesion, aggregation, and deposition of platelets onto ECM. Thus, we suggest that the novel nonpeptidic mimetics of RGD described herein, which were shown to be resistant to proteolytic digestion, would be valuable in novel therapeutic approaches to treat in RGD-dependent pathological disorders involving platelet-ECM interactions.

• References

• 1 George JN, Nurden AT, Phillips DR. Molecular defects in interaction of platelets with vessel wall. N Engl J Med 1984; 311: 1084-1098
• 2 Sakariassen KS, Nievelstein PFEM, Coller BS, Sixma JJ. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Brit J Haematol 1986; 63: 681-691
• 3 Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-1240
• 4 Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. Shear rate dependent decrease of adhesion in von Willebrand’s disease and Bemard-Soulier syndrome. J Lab Clin Med 1978; 92: 750-764
• 5 Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 1989; 83: 288-297
• 6 Yamada K, Kennedy DW. Dualistic nature of adhesive protein function: Fibronectin and its biologically active peptide fragments can autoinhibit fibronectin function. J Cell Biol 1984; 99: 29-36
• 7 Hynes RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell 1992; 69: 11-25
• 8 Ruoslathi E. Fibronectin and its receptors. Annu Rev Biochem 1988; 57: 375-391
• 9 D’Souza SE, Ginsberg MH, Matsueda GR, Plow EF. A discrete sequence in a platelet integrin is involved in ligand recognition. Nature 1991; 350: 66-68
• 10 Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-434
• 11 Ruoslathi E, Giancotti FG. Integrins and tumor cell dissemination. Cancer Cells 1989; 1: 119-126
• 12 Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986; 233: 467-470
• 13 Wong A, Hwang SM, Johansen K, Stadel JM, Powers DA, Bennet D, Heys R, Ali F, Bondinell W, Ku T, Samanen J. Cationic dependent binding of [³H]-SK&F 107260, a cyclic Arg-Gly-Asp (RGD) peptide to glycoprotein IIb-IIIa: Competitive inhibition by Fg g dodecapeptide and cyclic RGD peptides. J Cell Biochem 1992; (S) 16F: 181
• 14 Greenspoon N, Hershkovitz R, Alon R, Varon D, Shenkman B, Marx G, Federman S, Kapustina G, Lider O. Structural analysis of integrin recognition and inhibition of integrin-mediated cell functions by novel nonpeptidic surrogates of the Arg-Gly-Asp sequence. Biochemistry 1993; 32: 1001-1008
• 15 Barany N, Merrifield RB. The Peptides, Analysis, Synthesis and Biology. Gross E. ed. New York: Academic Press; 1980: 2
• 16 Taub R, Gould RJ, Garsky VM, Ciccarone TM, Hoxie J, Friedman PA, Shattil SJ. A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen. J Biol Chem 1989; 264: 259-265
• 17 Plow EF, Marguerie G. Inhibition of fibrinogen binding to human platelets by the tetrapeptide glycyl-L-prolyl-L-proline. Proc Natl Acad Sci USA 1982; 79: 3711-3715
• 18 Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969; 48: 963-974
• 19 Lider O, Mekori Y, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, Cohen IR, Naparstek Y. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell mediated immunity. Eur J Immunol 1990; 20: 493-499
• 20 Lavee J, Martinowitz U, Mohr R, Goor D, Golan M, Langsam J, Malik Z, Savion N. The effect of transfusion of fresh whole blood versus platelet concentrates after cardiac operation. J Thora Cardiovasc Surg 1989; 97: 204-212
• 21 Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Caufield G, Chang G, Hendrickson T, Still WC. MacroModel – An Integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 1990; 11: 440-446
• 22 Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemostas 1992; 67: 594-599
• 23 Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors: a dual role for glycoprotein IIb-IIIa (integrin α_IIbβ₃) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267: 11300-11306
• 24 De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. Von Willebrand factor interaction with the glycoprotein IIb-IIIa complex: Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 1986; 77: 1272-1277
• 25 Petersen DM, Stathopoulos NA, Giorgio TD, Heliums JD, Moake JL. Shear induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood 1987; 69: 625-628
• 26 Elices MJ, Urry A, Hemler ME. Receptor functions for the integrin VLA-3: Fibronectin, collagen and laminin binding are differentially influenced by Arg-Gly-Asp peptide and by divalent cations. J Cell Biol 1991; 112: 169-181
• 27 Frelinger AL, 3d Lam SC, Plow EF, Smith MA, Loftus JC, Ginsberg MW. Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion. J Biol Chem 1988; 263: 12397-12402
• 28 Tomiyama Y, Brojer E, Ruggeri ZM, Shatil SJ, Smiltneck J, Gorski J, Kumar A, Kieber-Emmons T, Kunicki TJ. A molecular model of RGD ligands. Antibody D gene segment that direct specificity for the integrin α_IIb-β₃ . J Biol Chem 1992; 267: 18085-18092
• 29 Kopple KD, Baures PW, Bean JW, D’Ambrosio CA, Hughes JL, Peishoff CE, Eggleston DS. Conformation of Arg-Gly-Asp Containing Cyclic Peptides: Solution and Crystal Studies. J Amer Chem Soc 1992; 114: 9615-9622
• 30 Ross R. The pathogenesis of atherosclerosis – an update. New Engl J Med 1986; 314: 488-500
• 31 McDowel RS, Gadek TR. Structural studies of potent RGD peptides. J Amer Chem Soc 1992; 114: 9245-92450
• 32 Eldor A, Vlodavsky I, Martinowitz U, Fuks Z, Coller BS. Platelet interaction with subendothelial extracellular matrix: Platelet-fibrinogen interactions are essential for platelet aggregation but not for the matrix induced release reaction. Blood 1985; 65: 1477-1483
• 33 Dardik R, Ruggeri ZM, Savion N, Gitel S, Martinowitz U, Chu V, Varon D. Platelet aggregation on extracellular matrix: Effect of a recombinant GPIb-binding fragment of von Willebrand factor. Thromb Haemost. In Press
• 34 Du XP, Plow EF, Frelinger AL, O’Toole TE, Loftus JC, Ginsberg MH. Ligands “activate” integrin allb-b3 (platelet GPIIb-IIIa). Cell 1991; 65: 409-416
• 35 Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 1992; 80: 2539-2547
• 36 Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993; 268: 1066-1073
• 37 Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, Nannizzi L, Charo IF, Barbourin A. GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 1991; 266: 9359-9362